Prosensa Holding

Prosensa Holding B.V. devel­oped ther­a­peu­tics on the basis of RNA mod­u­la­tion, there­by inter­ven­ing in an inter­me­di­ate step in pro­tein biosyn­the­sis.

The company’s lead pro­gram was in Duchenne Muscular Dystrophy (DMD), a genet­ic dis­or­der that blocks the syn­the­sis of an impor­tant pro­tein. DMD leads to pro­gres­sive paral­y­sis and even­tu­al­ly to death.

Portfolio: MedSciences Capital B.V. and MedSciences Capital II B.V.

Current stage: Acquired by Biomarin.